For Immediate Release
Chicago, IL – August 17, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Biogen Idec (BIIB), Alnylam Pharmaceuticals (ALNY), Isis Pharmaceuticals, Inc. (ISIS), AstraZeneca (AZN) and Sanofi (SNY).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Biogen Inks Deal with Regulus
Regulus Therapeutics Inc. and Biogen Idec (BIIB) recently entered into a deal to identify microRNAs (micro-RiboNucleic Acids) as biomarkers for multiple sclerosis (MS). As per the terms of the deal, Regulus – a joint venture between Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS) – will receive upfront fees and milestone payments. Biogen will also make an investment in Regulus.
Biogen is the market leader in therapies for the treatment of MS. The company markets several MS drugs including Avonex and Tysabri. Biogen is working on consolidating its position in the MS market and has an impressive late-stage pipeline of drugs including oral MS candidate, BG-12.
Biogen believes that the use of microRNA biomarkers will enable better assessment of early stage MS candidates. Moreover, MicroRNA biomarkers have the potential to assist in the selection of optimal patient segments for clinical trials, developing companion diagnostics and monitoring disease progression or relapse.
We believe that the partnership with a big player like Biogen will help boost the development of Regulus’ microRNA therapeutics. Regulus is evaluating microRNA therapeutics in several areas including oncology, fibrosis, hepatitis C and metabolic diseases.
A few days ago, AstraZeneca (AZN) and Regulus entered into an agreement to discover, develop, and commercialize microRNA therapeutics for three pre-clinical candidates. Regulus has collaborated with several companies, including Sanofi (SNY), for microRNA therapeutics.
We currently have an Outperform recommendation on Biogen. Biogen carries a Zacks #1 Rank (short-term Strong Buy rating). Currently, we have a Neutral recommendation on Isis Pharma and Outperform recommendation on Alnylam. Both stocks carry a Zacks #3 Rank (short-term Hold rating).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com